Abstract
Retinoblastoma is the most common primary malignant cancer of the eye in children arising in the developing retina. Depending on tumour stage, number of tumour foci, localization and size of tumours within the eye, presence of vitreous seeding, metastatic situations, age and health of the child, and the family’s wishes, doctors choose different therapies for retinoblastoma patients. The traditional treatment options include enucleation, cryotherapy, laser photocoagulation, thermotherapy, systemic chemotherapy, radiation therapy, or a combination of these. In recent years, in order to achieve the maximum concentrations of chemotherapy close to the tumour and in the vitreous, intra-arterial chemotherapy, intravitreal chemotherapy and pars plana vitrectomy (PPV) have emerged as potential therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mendoza PR, Grossniklaus HE. The biology of retinoblastoma. Prog Mol Biol Transl Sci. 2015;134:503–16.
Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203–12.
Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma. Oncogene. 2018;37(12):1551–60.
Mallipatna AC, Sutherland JE, Gallie BL, et al. Management and outcome of unilateral retinoblastoma. J AAPOS. 2009;13:546–50.
Stallard HB. Radiotherapy of malignant intraocular neoplasms. Br J Ophthalmol. 1948;32:618–39.
Moore RF, Stallard HB, Milner JG. Retinal gliomata treated by radon seeds. Br J Ophthalmol. 1931;15:673–96.
Stallard HB. The treatment of retinoblastoma. Ophthalmologica. 1966;151:214–30.
Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357–63.
Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23:2272–9.
Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1339–43.
Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthal- mol. 1996;114:1348–56.
Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1330–8.
Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321–8.
Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52:637–43.
Wong JR, Morton LM, Tucker MA, et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32:3284–90.
Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661–71.
Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569–77.
Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378–83.
Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41–53.
Suzuki S, Yamane T, Mohri M, et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.
Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33:601–7.
Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intra-arterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology. 2008;115:1398–404.
Gobin Y, Dunke IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732–7.
Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: Report no. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129:1399–406.
Abramson DD, Dunkel IJ, Brodie SE, et al. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010;128:370–2.
Francis J, Gobin Y, Dunkel I, et al. Carboplatin 1/− topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One. 2013;8:e72441.
Schaiquevich P, Ceciliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013;60:766–70.
Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96:499–502.
Gobin Y, Dunkel I, Marr BP, et al. Combined, sequential intravenous and intra- arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7:e44322.
De la Huerta I, Seider MI, Hetts SW, et al. Delayed cerebral infarction following intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol. 2016 Jun 1;134(6):712–4.
Gobin Y, Rosenstein LM, Marr BP, et al. Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2012;130:403–5.
Vijayakrishnan R, Shields CL, Ramasubramanian A, et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol. 2010;128:1427–31.
Manjandavida FP, Honavar SG, Reddy VA, et al. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology. 2014;121:517–24.
Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015;122:1173–9.
Moulin AP, Gaillard MC, Balmer A, et al. Ultrasound biomicroscopy evaluation of anterior extension in retinoblastoma: a clinicopathological study. Br J Ophthalmol. 2012;96:337–40.
Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810–7.
Francis JH, Marr BP, Brodie SE, et al. Anterior ocular toxicity of Intravitreous Melphalan for retinoblastoma. JAMA Ophthalmol. 2015;133:1459–63.
Zhao J, Li S, Shi J, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. Br J Ophthalmol. 2011;95(10):1372–5.
Abramson DH, Beaverson KL, Chang ST, et al. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316–23.
Seregard S, Singh AD. Retinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavity. Br J Ophthalmol. 2012;96:473–4.
Honavar SG, Shields CL, Shields JA, et al. Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol. 2001;119:1613–21.
Moshfeghi DM, Wilson MW, Grizzard S, et al. Intraocular surgery after treatment of germline retinoblastoma. Arch Ophthalmol. 2005;123:1008–12.
Shimoda Y, Hamano R, Ishihara K, et al. Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2008;246:501–8.
Ohshima K, Kaneko T, Takagi S, et al. Clinicopathological investigation of a retinoblastoma eye enucleated after vitreous surgery with melphalan perfusion. Jpn J Ophthalmol. 2009;53:186–8.
Yarovoy AA, Ushakova TL, Gorshkov IM, et al. Intraocular surgery with melphalan irrigation for vitreous hemorrhage in an only eye with retinoblastoma. Eur J Ophthalmol. 2015 Dec 1;26(1):e17–9.
Warden SM, Mukai S. Pars plana vitrectomy in eyes treated for retinoblastoma. Retina. 2006 Sep;26(7 Suppl):S53–6.
Ji X-D, Lu S-L, Zhao P-Q. Vitrectomy for localized vitreous seeds of retinoblastoma in an only eye. Chinese Med J. 2013;126:2589–90.
Zhao J, Li Q, Wu S, et al. Pars Plana vitrectomy and Endoresection of refractory intraocular retinoblastoma. Ophthalmology. 2018 Feb;125(2):320–2.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zhao, J., Yan, H. (2019). Retinoblastoma: Evolving Therapies. In: Berry, J., Kim, J., Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-11123-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-11123-6_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-11122-9
Online ISBN: 978-3-030-11123-6
eBook Packages: MedicineMedicine (R0)